日光角化症治療の世界市場レポート 2025年

日光角化症治療の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.0％で46億9,000万米ドルに成長します。予測期間の成長は、患者教育とエンゲージメント、デジタルヘルスの統合、認知度の向上、予防皮膚科学への注力、個別化医療の動向に起因します。予測期間の主な動向には、併用療法へのシフト、技術の進歩、個別化治療アプローチ、罹患率の増加、低侵襲治療などが含まれます。

光線性角化症の有病率の上昇は、日光角化症治療市場の成長軌道を牽引すると予測されます。光線性角化症は、長時間の日光曝露の結果として、ざらざらしたうろこ状の皮膚斑として現れ、前がん病変を緩和するための治療が必要となります。光線性角化症患者の急増は、治療オプションに対する需要の高まりを強調し、医薬品研究を推進し、局所治療の使用を提唱しています。世界がん研究基金インターナショナルの2022年2月の報告書によると、光線性角化症の発生率は、2020年の新規症例数150,000件以上から2022年には197,700件に急増し、この症状への対処における治療進歩の極めて重要な役割を強調しています。

高齢者人口の拡大は、日光角化症治療市場の成長軌道を推進する重要なカタリストとなる見込みです。特に65歳以上の高齢者層は、長時間の日光暴露や皮膚の老化により光線性角化症にかかりやすいため、そのニーズに対応することが極めて重要です。日光角化症治療の介入は、前がん性皮膚病変を抑制し、結果としてこの層の皮膚がんリスクを減少させる上で極めて重要です。2022年10月の世界保健機関の予測によると、60歳以上の人口は2020年の10億人から2030年には14億人に急増し、2050年には21億人に倍増すると推定されています。この人口動態の変化は、光線性角化症に罹患しやすい老年人口に対応した集中治療の必要性を強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の日光角化症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の日光角化症治療市場：成長率分析
• 世界の日光角化症治療市場の実績：規模と成長, 2019-2024
• 世界の日光角化症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の日光角化症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の日光角化症治療市場：治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所治療
• モダリティステップ
• 光線力学的療法
• その他の治療
• 世界の日光角化症治療市場：医薬品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フルオロウラシルクリーム
• イミキモドクリーム
• インゲノールメブテートゲル
• ジクロフェナクゲル
• 世界の日光角化症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 民間皮膚科クリニック
• レーザー治療センター
• がん治療センター
• スパと若返りセンター
• ホームケア
• 世界の日光角化症治療市場：局所治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 5-フルオロウラシル（5-FU）
• イミキモド
• インゲノールメブテート
• ジクロフェナク
• 世界の日光角化症治療市場：モダリティステップのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 凍結療法
• 掻爬術と電気手術
• レーザー治療
• ケミカルピーリング
• 世界の日光角化症治療市場：光線力学的療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ALAベースのPDT
• MALベースのPDT
• 世界の日光角化症治療市場：その他の治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫療法
• 光線療法
• 併用療法

第7章 地域別・国別分析

• 世界の日光角化症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の日光角化症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 日光角化症治療市場：競合情勢
• 日光角化症治療市場：企業プロファイル
  • Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Hill Dermaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • LEO Pharma A/S Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Almirall SA
• Biofrontera AG
• Galderma SA
• Mylan NV
• Cipher Pharmaceuticals Inc.
• Pierre Fabre Pharmaceuticals Inc.
• Tolmar Pharmaceuticals Inc.
• Stanford Chemicals Company
• Glaxo Smith Kline PLC
• Alma Lasers Ltd.
• 3M Company
• Nestle SA
• Cutanea Life Sciences Inc.
• DUSA Pharmaceuticals Inc.
• Foamix Pharmaceuticals Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 日光角化症治療市場2029：新たな機会を提供する国
• 日光角化症治療市場2029：新たな機会を提供するセグメント
• 日光角化症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Actinic keratoses treatment addresses the skin condition resulting from sun exposure, primarily manifesting on the face, scalp, backs of the hands, or chest. This treatment aims to mitigate the risk of developing the condition by safeguarding the skin from ultraviolet (UV) rays and minimizing regular sun exposure.

The primary categories of actinic keratosis treatment include topical applications, procedural interventions, photodynamic therapy, and other modalities. Topical treatment involves the application of specific medications like fluorouracil cream, imiquimod cream, ingenol mebutate gel, and diclofenac gel. These medications are utilized across various healthcare settings, including hospitals, private dermatology clinics, laser therapy centers, cancer treatment facilities, spas, rejuvenation centers, and in homecare practices.

The actinic keratosis treatment market research report is one of a series of new reports from The Business Research Company that provides actinic keratosis treatment market statistics, including actinic keratosis treatment industry global market size, regional shares, competitors with an actinic keratosis treatment market share, detailed actinic keratosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the actinic keratosis treatment industry. This actinic keratosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The actinic keratosis treatment market size has grown strongly in recent years. It will grow from $3.2 billion in 2024 to $3.44 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to treatment adherence, market competition, patient education initiatives, dermatological practices, research and clinical trials.

The actinic keratosis treatment market size is expected to see strong growth in the next few years. It will grow to $4.69 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to patient education and engagement, digital health integration, growing awareness, focus on preventive dermatology, personalized medicine trends. Major trends in the forecast period include shift towards combination therapies, technological advancements, personalized treatment approaches, increasing incidence rates, minimally invasive treatments.

The escalating prevalence of actinic keratosis is anticipated to drive the growth trajectory of the market for actinic keratosis treatment. Actinic keratosis, a consequence of prolonged sun exposure, manifests as rough, scaly skin patches and necessitates treatment to mitigate precancerous lesions. The surge in actinic keratosis cases underscores the amplified demand for treatment options, driving pharmaceutical research and advocating the use of topical treatments. According to the World Cancer Research Fund International's February 2022 report, the incidence of actinic keratosis surged from over 150,000 new cases in 2020 to 197,700 cases in 2022, emphasizing the pivotal role of treatment advancements in addressing this condition.

The expanding demographic of elderly individuals is poised to be a significant catalyst propelling the growth trajectory of the actinic keratosis treatment market. Addressing the needs of the geriatric populace-typically aged 65 and older-remains pivotal due to their susceptibility to actinic keratosis, attributed to prolonged sun exposure and skin aging. Actinic keratosis treatment interventions are crucial in curbing precancerous skin lesions, consequently reducing the risk of skin cancer among this demographic. As per the World Health Organization's projection in October 2022, the population aged 60 and above is estimated to surge from 1 billion in 2020 to 1.4 billion by 2030, with a subsequent doubling to 2.1 billion by 2050. This demographic shift underscores the necessity for focused treatments catering to the geriatric population susceptible to actinic keratosis.

Major companies in the actinic keratosis treatment market are concentrating on developing innovative products, such as prescription medications, to enhance treatment efficacy, improve patient outcomes, and broaden their product offerings. Prescription medications are drugs that can only be dispensed with a healthcare provider's written authorization, specifying the medication name, dosage, and duration. These drugs are intended for treating specific medical conditions and necessitate careful monitoring due to potential side effects. For example, in December 2022, Biofrontera AG, a Germany-based pharmaceutical company, introduced Ameluz, a topical gel containing 5-aminolevulinic acid. This gel is used in conjunction with photodynamic therapy (PDT) to treat mild to moderate actinic keratoses (AK) and certain types of basal cell carcinoma. The treatment involves applying the gel to the affected skin areas, followed by exposure to light from a BF-RhodoLED lamp, which activates the medication.

Leading companies in the actinic keratosis treatment market are prioritizing advancements in technologies like positioning sensors to boost treatment accuracy, enhance patient outcomes, and optimize therapy delivery by precisely targeting light or topical agents to the affected skin areas. Positioning sensor technology refers to systems that accurately identify the location of an object or surface, often utilized to guide and improve treatment in medical procedures. For example, in December 2022, Biofrontera Inc., a US-based biopharmaceutical firm, introduced the RhodoLED XL Lamp. This lamp is approved for use in conjunction with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, to treat mild-to-moderate actinic keratosis on the face and scalp. This approval highlights the lamp's role in enhancing the efficacy of photodynamic therapy (PDT).

In March 2022, Coegin Pharma, a Sweden-based company at the forefront of a phase I/II trial featuring their lead candidate AVX001 targeting actinic keratosis and actively engaged in the preclinical development of AVX420 for conditions like leukemia and chronic kidney disease, executed a merger with Follicum. This strategic alliance aimed to reinforce Coegin Pharma's drug development portfolio by placing a significant emphasis on tackling diabetes complications. Follicum, a biotech company based in Sweden, brings complementary expertise and resources to Coegin Pharma, fortifying its position in drug development and enhancing its focus on addressing various medical conditions.

Major companies operating in the actinic keratosis treatment market are Sun Pharmaceutical Industries Ltd., Novartis AG, Hill Dermaceuticals Inc., Bausch Health Companies Inc., LEO Pharma A/S, Almirall SA, Biofrontera AG, Galderma SA, Mylan NV, Cipher Pharmaceuticals Inc., Pierre Fabre Pharmaceuticals Inc., Tolmar Pharmaceuticals Inc., Stanford Chemicals Company, Glaxo Smith Kline PLC, Alma Lasers Ltd., 3M Company, Nestle SA, Cutanea Life Sciences Inc., DUSA Pharmaceuticals Inc., Foamix Pharmaceuticals Ltd., G&W Laboratories Inc., Hikma Pharmaceuticals PLC, Innocutis Holdings LLC, Mayne Pharma Group Limited, Meda AB, Merz Pharma GmbH & Co KGaA, Perrigo Company PLC, PharmaDerm A division of Fougera Pharmaceuticals Inc., Promius Pharma LLC, Ranbaxy Laboratories Limited, Sandoz International GmbH, Stiefel Laboratories Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Zydus Pharmaceuticals Inc., Dermira Inc., Menlo Therapeutics Inc., Sol-Gel Technologies Ltd., Verrica Pharmaceuticals Inc.

North America was the largest region in the actinic keratosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actinic keratosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the actinic keratosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The actinic keratoses treatment market includes revenues earned by entities by providing cryotherapy, laser therapy, chemical peels, and medications. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Actinic Keratosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on actinic keratosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for actinic keratosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The actinic keratosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Topical Treatment; Procedural Modality; Photodynamic Therapy; Other Treatments
• 2) By Medication: Fluorouracil Cream; Imiquimod Cream; Ingenol Mebutate Gel; Diclofenac Gel
• 3) By End User: Hospitals; Private Dermatology Clinics; Laser Therapy Centers; Cancer Treatment Centers; Spas And Rejuvenation Centers; Homecare
• Subsegments:
• 1) By Topical Treatment: 5-Fluorouracil (5-FU); Imiquimod; Ingenol Mebutate; Diclofenac
• 2) By Procedural Modality: Cryotherapy; Curettage And Electrosurgery; Laser Therapy; Chemical Peels
• 3) By Photodynamic Therapy: ALA-Based PDT; MAL-Based PDT
• 4) By Other Treatments: Immunotherapy; Phototherapy; Combination Therapies
• Companies Mentioned: Sun Pharmaceutical Industries Ltd.; Novartis AG; Hill Dermaceuticals Inc.; Bausch Health Companies Inc.; LEO Pharma A/S
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Actinic Keratosis Treatment Market Characteristics

3. Actinic Keratosis Treatment Market Trends And Strategies

4. Actinic Keratosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Actinic Keratosis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Actinic Keratosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Actinic Keratosis Treatment Market Growth Rate Analysis
• 5.4. Global Actinic Keratosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Actinic Keratosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Actinic Keratosis Treatment Total Addressable Market (TAM)

6. Actinic Keratosis Treatment Market Segmentation

• 6.1. Global Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Treatment
• Procedural Modality
• Photodynamic Therapy
• Other Treatments
• 6.2. Global Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Flurouracil Cream
• Imiquimod Cream
• Ingenol Mebutate Gel
• Diclofenac Gel
• 6.3. Global Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Private Dermatology Clinics
• Laser Therapy Centers
• Cancer Treatment Centers
• Spas and Rejuvenation Centers
• Homecare
• 6.4. Global Actinic Keratosis Treatment Market, Sub-Segmentation Of Topical Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 5-Fluorouracil (5-FU)
• Imiquimod
• Ingenol Mebutate
• Diclofenac
• 6.5. Global Actinic Keratosis Treatment Market, Sub-Segmentation Of Procedural Modality, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cryotherapy
• Curettage And Electrosurgery
• Laser Therapy
• Chemical Peels
• 6.6. Global Actinic Keratosis Treatment Market, Sub-Segmentation Of Photodynamic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• ALA-Based PDT
• MAL-Based PDT
• 6.7. Global Actinic Keratosis Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunotherapy
• Phototherapy
• Combination Therapies

7. Actinic Keratosis Treatment Market Regional And Country Analysis

• 7.1. Global Actinic Keratosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Actinic Keratosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Actinic Keratosis Treatment Market

• 8.1. Asia-Pacific Actinic Keratosis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Actinic Keratosis Treatment Market

• 9.1. China Actinic Keratosis Treatment Market Overview
• 9.2. China Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Actinic Keratosis Treatment Market

• 10.1. India Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Actinic Keratosis Treatment Market

• 11.1. Japan Actinic Keratosis Treatment Market Overview
• 11.2. Japan Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Actinic Keratosis Treatment Market

• 12.1. Australia Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Actinic Keratosis Treatment Market

• 13.1. Indonesia Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Actinic Keratosis Treatment Market

• 14.1. South Korea Actinic Keratosis Treatment Market Overview
• 14.2. South Korea Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Actinic Keratosis Treatment Market

• 15.1. Western Europe Actinic Keratosis Treatment Market Overview
• 15.2. Western Europe Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Actinic Keratosis Treatment Market

• 16.1. UK Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Actinic Keratosis Treatment Market

• 17.1. Germany Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Actinic Keratosis Treatment Market

• 18.1. France Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Actinic Keratosis Treatment Market

• 19.1. Italy Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Actinic Keratosis Treatment Market

• 20.1. Spain Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Actinic Keratosis Treatment Market

• 21.1. Eastern Europe Actinic Keratosis Treatment Market Overview
• 21.2. Eastern Europe Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Actinic Keratosis Treatment Market

• 22.1. Russia Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Actinic Keratosis Treatment Market

• 23.1. North America Actinic Keratosis Treatment Market Overview
• 23.2. North America Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Actinic Keratosis Treatment Market

• 24.1. USA Actinic Keratosis Treatment Market Overview
• 24.2. USA Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Actinic Keratosis Treatment Market

• 25.1. Canada Actinic Keratosis Treatment Market Overview
• 25.2. Canada Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Actinic Keratosis Treatment Market

• 26.1. South America Actinic Keratosis Treatment Market Overview
• 26.2. South America Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Actinic Keratosis Treatment Market

• 27.1. Brazil Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Actinic Keratosis Treatment Market

• 28.1. Middle East Actinic Keratosis Treatment Market Overview
• 28.2. Middle East Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Actinic Keratosis Treatment Market

• 29.1. Africa Actinic Keratosis Treatment Market Overview
• 29.2. Africa Actinic Keratosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Actinic Keratosis Treatment Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Actinic Keratosis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Actinic Keratosis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Actinic Keratosis Treatment Market Competitive Landscape
• 30.2. Actinic Keratosis Treatment Market Company Profiles
  • 30.2.1. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Hill Dermaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. LEO Pharma A/S Overview, Products and Services, Strategy and Financial Analysis

31. Actinic Keratosis Treatment Market Other Major And Innovative Companies

• 31.1. Almirall SA
• 31.2. Biofrontera AG
• 31.3. Galderma SA
• 31.4. Mylan NV
• 31.5. Cipher Pharmaceuticals Inc.
• 31.6. Pierre Fabre Pharmaceuticals Inc.
• 31.7. Tolmar Pharmaceuticals Inc.
• 31.8. Stanford Chemicals Company
• 31.9. Glaxo Smith Kline PLC
• 31.10. Alma Lasers Ltd.
• 31.11. 3M Company
• 31.12. Nestle SA
• 31.13. Cutanea Life Sciences Inc.
• 31.14. DUSA Pharmaceuticals Inc.
• 31.15. Foamix Pharmaceuticals Ltd.

32. Global Actinic Keratosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Actinic Keratosis Treatment Market

34. Recent Developments In The Actinic Keratosis Treatment Market

35. Actinic Keratosis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Actinic Keratosis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Actinic Keratosis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Actinic Keratosis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer